摘要
目的:研究新型ATP敏感性钾通道(KATP)开放剂埃他卡林对内皮素-1(ET-1)诱导的人肺动脉平滑肌细胞(HPASMCs)上KATP蛋白表达的影响。方法:原代培养人肺动脉平滑肌细胞,随机分成对照组,ET-1组,ET-1+埃他卡林组,ET-1+吡那地尔组,ET-1+埃他卡林+格列本脲组,ET-1+吡那地尔+格列本脲组,用Western-blot方法分析各组KATP蛋白磺酰脲受体亚单位(SUR2B)和内向整流性孔区亚单位(Kir6.1)表达变化情况。结果:与ET-1的作用相反,埃他卡林能使ET-1诱导下的SUR2B亚基表达升高,特异性KATP阻断剂格列本脲可逆转埃他卡林引起的SUR2B亚基表达升高;但各组对Kir6.1亚基表达无明显影响。结论:埃他卡林通过上调KATP的SUR2B亚基表达而发挥其在治疗低氧性肺动脉高压(HPH)中的作用,可望成为治疗低氧性肺动脉高压的新药。
Objective:To investigate the effects of Iptakalim, a novel ATP-sensitive potassium channel opener (KATPCO),on the expression of ATP-sensitive potassium channel (KATP) protein in cultured human pulmonary artery smooth muscle cells(HPASMCs) induced by endothelin-I (ET-I). Methods:By WesteIn-blot analysis,the expression of both SUR2B and Kir6.1 ,subunits of KATP protein, was detected in primary cultured HPASMCs, which were randomly divided into control group, ET-I group, ET-I + Iptakalim group, ET-I+ Pinacidil group,ET-l+ Iptakalim+ Glibenclamide group and ET-I + Pinacidil+ Glibenclamide group. Results:Compared with ET-1, Iptakalim could upregulate the SUR2B subunit expression,which could be inhibited by Glibenclamide,a particular ATP-sensitive potassium channel blocker. However, there was no significant difference in Kir6.1 subunit expression in each group. Conclusion: Iptakalim,a new potential candidate in the treatment of hypoxic pulmonary hypertension (HPH) ,could play an important role by upregulating the expression of SUR2B subunit.
出处
《南京医科大学学报(自然科学版)》
CAS
CSCD
北大核心
2008年第3期304-307,共4页
Journal of Nanjing Medical University(Natural Sciences)
基金
江苏省自然科学基金资助项目(BK2006246)
南京医科大学创新基金(CX2003002)